XOMA Royalty Corporation Completes Acquisition of Turnstone Biologics Corp
I'm PortAI, I can summarize articles.
XOMA Royalty Corporation has completed its acquisition of Turnstone Biologics Corp. on August 11, 2025. The acquisition involved a successful tender offer where XOMA purchased all outstanding shares of Turnstone’s common stock for $0.34 per share in cash, along with a contingent value right (CVR) for potential future payments. Following the transaction, Turnstone is now a wholly owned subsidiary of XOMA and will continue its operations under the new ownership.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments